HAC (Russian)
RSCI (Russian)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

Phenotypes of asthma in women of childbearing age

DOI: https://doi.org/10.29296/25877305-2021-11-09

O. Lavrova, MD; Professor M. Petrova, MD; L. Georgieva I.P. Pavlov First Saint Petersburg State
Medical University

The ways for the development of severe asthma in young people cannot be considered to have been fully studied at present. Objective: to analyze the etiopathogenetic features and nature of asthma during pregnancy in 2440 asthmatic women of childbearing age. Subjects and methods. A clinical and functional examination and follow-up were performed in 2440 pregnant asthmatic women of childbearing age. Results. The allergic mechanism for asthma development prevailed in women of childbearing age. With the addition of an aspirin mechanism and in the presence of a purely aspirin mechanism, the severity of the disease increased substantially. Chronic polypous rhinosinusitis was an additional aggravating factor for asthma. The highest average number of eosinophilic leukocytes was determined in the group of patients with an aspirin mechanism. The greatest increase in immunoglobulin E levels was seen in the group with an allergic mechanism of the disease. The analysis of the nature of complications of pregnancy, childbirth, and the status of newborns revealed no features in patients with the mechanism of aspirin-induced asthma. Conclusion. The treatment of patients with asthma, especially with its severe course, should be performed, by taking into account the mechanisms of this disease and include targeted therapy drugs.

mechanisms of development

  1. Rachemann F.M. A clinical classification of Asthma based on a review of 648 cases. Am J Med Sci. 1921; 162: 802–12.
  2. Global Strategy For Asthma Management And Prevention Nhlbi/Who Workshop Report (Based on a March 1993 Meeting) National Institutes Of Health National Heart, Lung, and Blood Institute Publication Number 95-3659 January 1995. Documents available from: www.ginasthma.org
  3. Fedoseev G.B., Hlopotova G.P. Bronhial'naja astma: monografija. L.: Meditsina, 1988; s. 15–7 [Fedoseev G.B., Khlopotova G.P. Bronkhial’naya astma: monografiya. L.: Meditsina, 1988; s. 15–7 (in Russ.)].
  4. Lommatzsch M. et al. Severe Asthma: Definition, Diagnosis and Treatment. Dtsch Arztebl Int. 2014; 111 (50): 847–55. DOI: 10.3238/arztebl.2014.0847
  5. Niespodziana K., Borochova K., Pazderova P. et al. Toward personalization of asthma treatment according to trigger factors. J Allergy Clin Immunol. 2020; 145 (6): 1529–34. DOI: 10.1016/j.jaci.2020.02.001
  6. Federal'nye klinicheskie rekomendatsii po diagnostike i lecheniju bronhial'noj astmy (2019) [Federal’nye klinicheskie rekomendatsii po diagnostike i lecheniyu bronkhial’noi astmy (2019) (in Russ.)]. URL: https://spulmo.ru/
  7. McGregor M.Cl., Krings J.G., Nair P. et al. Role of Biologics in Asthma. Review. Am J Respir Crit Care Med. 2019; 199 (4): 433–45. DOI: 10.1164/rccm.201810-1944CI
  8. Scow D.T., Luttermoser G.K., Dickerson K.S. Leucotriene Inhibitors in the treatment of Allergy and Asthma. Am Fam Physician. 2007; 75 (1): 65–70.
  9. Nenasheva N.M. T2-bronhial'naja astma: harakteristika endotipa i biomarkery. Pul'monologija. 2019; 29 (2): 216–28 [Nenasheva N.M. T2-high and T2-low bronchial asthma, endotype characteristics and biomarkers. Pulmonologiya. 2019; 29 (2): 216–28 (in Russ.)]. DOI: 10.18093/0869-0189-2019-29-2-216-228
  10. Bousquet J., Mantzouranis E., Cruz A.A. et al. Uniformdefinition of asthma severity, control, and exacerbations:document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol. 2010; 126 (5): 926–38. DOI: 10.1016/j.jaci.2010.07.019.8
  11. Namazy J.A., Schatz M. Management of Asthma during Pregnancy: Optimizing Outcomes and Minimizing Risk. Semin Respir Crit Care Med. 2018; 39 (1): 29–35. DOI: 10.1055/s-0037-1606216